<?xml version="1.0" encoding="UTF-8"?>
<p>On account of their best scores achieved in the docking study (
 <xref rid="t0003" ref-type="table">Table 3</xref>) as well as their efficient anti-proliferative actions towards both the examined breast cancer cell lines (
 <xref rid="t0001" ref-type="table">Table 1</xref>), pyridazines 
 <bold>11e</bold>, 
 <bold>11h</bold>, 
 <bold>11l</bold>, and 
 <bold>11m</bold> were selected to be examined for their ability to inhibit CDK2. The results have been obtained as IC
 <sub>50</sub> values which listed in 
 <xref rid="t0005" ref-type="table">Table 5</xref>.
</p>
